Cover Image
市場調查報告書

脫髮症:開發中產品分析

Alopecia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192456
出版日期 內容資訊 英文 168 Pages
訂單完成後即時交付
價格
Back to Top
脫髮症:開發中產品分析 Alopecia - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 168 Pages
簡介

脫髮症是指局部或是完全脫髮,尤其是看得見頭皮,常見於頭部整體或是局部,甚至全身脫毛。最顯著的症狀是頭髮變少。致病因子有過敏、刺激物、毒素、燒燙傷、外傷、感染疾病等。

本報告提供脫髮症的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

脫髮症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • Valeant Pharmaceuticals International, Inc.
  • 大正製藥
  • AntiCancer, Inc.
  • Panacea Biotec Limited
  • ProCertus BioPharm Inc.
  • AndroScience Corporation
  • Hygeia Therapeutics, Inc.
  • Kuhnil Pharmaceutical Co., Ltd.
  • Lee's Pharmaceutical Holdings Limited
  • Berg Pharma, LLC
  • vida therapeutics inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abatacept
  • ruxolitinib
  • CB-0301
  • calcitriol
  • Small Molecule Antagonists To Transforming Growth Factor Beta Receptor For Alopecia, Pulmonary Fibrosis And Dermatology
  • ZK-003
  • HYG-430
  • HYG-420
  • HYG-410
  • ASCJ-9
  • KI-1104
  • Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis
  • V-2248
  • ProDermaCel
  • Lipo-4MA
  • KI-1105
  • Drug to Agonize P2Y5-Ligand LPA for Alopecia
  • Drug For Autoimmune Disorders
  • Drugs to Inhibit PAI-1 for Thromboembolic Disease, PCOS and Alopecia
  • Peptide For Hair Regeneration

開發中產品的最新趨勢

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8292IDB

Summary

Global Markets Direct's, 'Alopecia - Pipeline Review, H2 2016', provides an overview of the Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alopecia
  • The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects
  • The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alopecia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alopecia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alopecia Overview
  • Therapeutics Development
    • Pipeline Products for Alopecia - Overview
    • Pipeline Products for Alopecia - Comparative Analysis
  • Alopecia - Therapeutics under Development by Companies
  • Alopecia - Therapeutics under Investigation by Universities/Institutes
  • Alopecia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Alopecia - Products under Development by Companies
  • Alopecia - Products under Investigation by Universities/Institutes
  • Alopecia - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos S/A
    • Aclaris Therapeutics, Inc.
    • Allergan Plc
    • Almirall, S.A.
    • AndroScience Corporation
    • Berg LLC
    • BiologicsMD, Inc.
    • Bristol-Myers Squibb Company
    • Concert Pharmaceuticals, Inc.
    • Diffusion Pharmaceuticals Inc.
    • Follicum AB
    • Handok Inc.
    • Histogen, Inc.
    • Hyundai Pharmaceutical Co., Ltd.
    • Incyte Corporation
    • Kuhnil Pharmaceutical Co., Ltd.
    • Lee's Pharmaceutical Holdings Limited
    • LEO Pharma A/S
    • NovaLead Pharma Pvt. Ltd.
    • Novartis AG
    • Panacea Biotec Limited
    • Quark Pharmaceuticals, Inc.
    • RepliCel Life Sciences, Inc.
    • RXi Pharmaceuticals Corporation
    • Sucampo Pharmaceuticals, Inc.
    • SWITCH Biotech LLC
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • TetraLogic Pharmaceuticals
    • Tigo GmbH
    • Valeant Pharmaceuticals International, Inc.
    • Vida Therapeutics Inc.
  • Alopecia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
    • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
    • Antisense Oligonucleotide to Antagonize Androgen Receptor for Alopecia - Drug Profile
    • ASCJ-9 - Drug Profile
    • ATI-50001 - Drug Profile
    • ATI-50002 - Drug Profile
    • bimatoprost - Drug Profile
    • BMD-1141 - Drug Profile
    • BMD-1341 - Drug Profile
    • BMD-2341 - Drug Profile
    • BQ-A - Drug Profile
    • BRM-421 - Drug Profile
    • calcitriol - Drug Profile
    • CB-0301 - Drug Profile
    • CTP-543 - Drug Profile
    • DHL-HisZnNa - Drug Profile
    • diphencyprone - Drug Profile
    • finasteride - Drug Profile
    • finasteride - Drug Profile
    • FOL-005 - Drug Profile
    • FS-2 - Drug Profile
    • Hair Stimulating Complex - Drug Profile
    • HL-5945 - Drug Profile
    • HTB-005 - Drug Profile
    • interferon beta-1b - Drug Profile
    • KI-1104 - Drug Profile
    • KI-1105 - Drug Profile
    • LEO-124249 - Drug Profile
    • minoxidil - Drug Profile
    • NLP-602 - Drug Profile
    • OLX-104 - Drug Profile
    • PDI-38 - Drug Profile
    • QPAL-1 - Drug Profile
    • QPAL-2 - Drug Profile
    • RCH-01 - Drug Profile
    • Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile
    • remetinostat - Drug Profile
    • RES-440 - Drug Profile
    • RK-023 - Drug Profile
    • ruxolitinib phosphate - Drug Profile
    • secukinumab - Drug Profile
    • setipiprant - Drug Profile
    • SM-04554 - Drug Profile
    • Small Molecule for Androgenic Alopecia - Drug Profile
    • Small Molecules to Inhibit JAK for Alopecia Areata and Androgenetic Alopecia - Drug Profile
    • Small Molecules to Inhibit JAK3 for Alopecia and Dermatological Disorders - Drug Profile
    • Synthetic Peptide for Alopecia - Drug Profile
    • TASP-0382088 - Drug Profile
    • VTI-1000 Series - Drug Profile
    • ZK-003 - Drug Profile
  • Alopecia - Dormant Projects
  • Alopecia - Discontinued Products
  • Alopecia - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Alopecia, H2 2016
  • Number of Products under Development for Alopecia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Alopecia - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Alopecia - Pipeline by Aclaris Therapeutics, Inc., H2 2016
  • Alopecia - Pipeline by Allergan Plc, H2 2016
  • Alopecia - Pipeline by Almirall, S.A., H2 2016
  • Alopecia - Pipeline by AndroScience Corporation, H2 2016
  • Alopecia - Pipeline by Berg LLC, H2 2016
  • Alopecia - Pipeline by BiologicsMD, Inc., H2 2016
  • Alopecia - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Alopecia - Pipeline by Concert Pharmaceuticals, Inc., H2 2016
  • Alopecia - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
  • Alopecia - Pipeline by Follicum AB, H2 2016
  • Alopecia - Pipeline by Handok Inc., H2 2016
  • Alopecia - Pipeline by Histogen, Inc., H2 2016
  • Alopecia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Alopecia - Pipeline by Incyte Corporation, H2 2016
  • Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016
  • Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Alopecia - Pipeline by LEO Pharma A/S, H2 2016
  • Alopecia - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
  • Alopecia - Pipeline by Novartis AG, H2 2016
  • Alopecia - Pipeline by Panacea Biotec Limited, H2 2016
  • Alopecia - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Alopecia - Pipeline by RepliCel Life Sciences, Inc., H2 2016
  • Alopecia - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
  • Alopecia - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016
  • Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
  • Alopecia - Pipeline by TetraLogic Pharmaceuticals, H2 2016
  • Alopecia - Pipeline by Tigo GmbH, H2 2016
  • Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Alopecia - Pipeline by Vida Therapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Alopecia - Dormant Projects, H2 2016
  • Alopecia - Dormant Projects (Contd..1), H2 2016
  • Alopecia - Dormant Projects (Contd..2), H2 2016
  • Alopecia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Alopecia, H2 2016
  • Number of Products under Development for Alopecia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top